Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.

Launched by CHU DE QUEBEC-UNIVERSITE LAVAL · Mar 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two different types of radiation therapy for men with localized prostate cancer. Researchers want to find out if a new method called ultra-hypofractionated radiation (UH) is as safe as a more traditional approach called moderately hypofractionated radiation (MH). Both methods will be combined with a specific type of treatment called high-dose-rate (HDR) brachytherapy, which delivers targeted radiation directly to the tumor. The study will look at how well each treatment works and the side effects that patients may experience.

To participate in the trial, men aged 65 to 74 who have been diagnosed with early-stage prostate cancer are eligible, as long as certain criteria are met. This includes having a specific type of cancer that isn’t too advanced and a certain level of a blood marker called PSA. Participants can expect to receive the assigned radiation treatment and will be monitored for any side effects, as well as the effectiveness of the therapy over the next five to ten years. It’s important to understand that this trial is still recruiting participants, so those who qualify have the chance to contribute to important research in prostate cancer treatment.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Biopsy proven Prostate adenocarcinoma
• • Stage T1c, T2 (Annex 2)
• • Stage Nx or N0
• • Stage Mx or M0
• • PSA \< 20ng/ml
• • Gleason Score 6 or 7
• • Having the ability to sing a written consent
• Exclusion Criteria:
• • Age \< 18ans
• • Clinical Stage T3 or T4
• • Stage N1
• • Stage M1
• • PSA \> 20
• • Gleason Score 8 to 10
• • IPSS Score \> 20 alpha-blocking medication.
• • Prior pelvic radiotherapy.
• • History of active collagenosis (Lupus, Sclerodermia, Dermatomyosis)
• • Past history of Inflammatory Bowell Disease
• • Bilateral hip prosthesis